×
Arjun Oberoi

Arjun Oberoi

Managing Director - Everstone

Arjun Oberoi joined Everstone as Managing Director in 2018 and has been leading Everstone’s healthcare platform Everlife as Vice Chairman since 2017. He is an experienced investor with proven track record of investing in the healthcare sector globally and has more than 15 years of leadership
experience with major healthcare MNCs such as Stryker, Sanofi and Pfizer. Arjun was the global head of healthcare for Actis, founded Cure Capital in 2017 and began his corporate career as a consultant with McKinsey. He is a board certified physician in the UK, holds a Bachelor of Science in
Neuroscience and a Medical Degree in Medicine from the University of Edinburgh.

Copyright ©2021 all rights reserved

Hydroxyprogesterone

On April 6, 2023, the U.S. Food and Drug Administration (FDA) issued a final decision ordering the withdrawal of the approval of Makena® (hydroxyprogesterone caproate injection, 250 milligrams (mg) per mL) and its generics. FDA recognizes that there is a supply of product that has already been distributed. Patients who have questions should talk to their healthcare provider. We recommend health care practitioners consider FDA’s conclusions.

If you have questions or concerns about receiving your therapy as prescribed, consult your healthcare provider.

https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena